Clin2
NCT06891885Possibly a fitRecruiting

Safety study of DSP-3077 for retinitis pigmentosa

Retinitis Pigmentosa

Part of Eyes & vision, Genetic & congenital clinical trials.

This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have a diagnosis of retinitis pigmentosa that is not part of a syndrome.
  • You must agree to genetic testing if you haven't had it before.
  • Your vision in the study eye must be within a certain range (from hand motion up to about 20/200).
  • You must be generally healthy with no other eye diseases or unstable medical conditions.
  • If you are female, you cannot be pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06628947Recruiting· Phase 2
Testing KIO-301 eye injections for advanced retinitis pigmentosa

This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.

Sydney, New South Wales
NCT06242379Recruiting· Phase 1/Phase 2
Testing stem cell particles for retinitis pigmentosa

This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.

Bangkok Noi, Bangkok
NCT06574997AVAILABLE
Gene therapy for retinitis pigmentosa in adults

This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.

Phoenix, Arizona
NCT06952842Recruiting· Phase 1/Phase 2
Gene therapy trial for retinitis pigmentosa with RHO mutation

This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.

Beijing, Beijing Municipality
NCT06936787Recruiting· Phase 1
Study of IGT001 for retinitis pigmentosa

This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.

Shanghai
NCT06375239Recruiting
Study of tests for tracking vision in retinal disease

This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.

Irvine, California

Hear when a new Retinitis Pigmentosa trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.